CASI Pharmaceuticals Inc (CASI) - Total Liabilities
Based on the latest financial reports, CASI Pharmaceuticals Inc (CASI) has total liabilities worth $53.05 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CASI Pharmaceuticals Inc - Total Liabilities Trend (1994–2024)
This chart illustrates how CASI Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See CASI Pharmaceuticals Inc (CASI) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CASI Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of CASI Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brüder Mannesmann Aktiengesellschaft
F:BMM
|
Germany | €49.16 Million |
|
Callan JMB Inc. Common Stock
NASDAQ:CJMB
|
USA | $4.11 Million |
|
MEMPHASYS LTD
F:IG7
|
Germany | €5.59 Million |
|
Bang Overseas Limited
NSE:BANG
|
India | Rs1.03 Billion |
|
NCL International Logistics Public Company Limited
BK:NCL
|
Thailand | ฿562.45 Million |
|
Sdcl Energy Efficiency Income Trust PLC
LSE:SEIT
|
UK | GBX2.40 Million |
|
Alliance Pharma plc
LSE:APH
|
UK | GBX161.50 Million |
|
Corus Entertainment Inc
TO:CJR-B
|
Canada | CA$2.04 Billion |
Liability Composition Analysis (1994–2024)
This chart breaks down CASI Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CASI Pharmaceuticals Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CASI Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CASI Pharmaceuticals Inc (1994–2024)
The table below shows the annual total liabilities of CASI Pharmaceuticals Inc from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $51.82 Million | +1.41% |
| 2023-12-31 | $51.10 Million | +74.40% |
| 2022-12-31 | $29.30 Million | -3.42% |
| 2021-12-31 | $30.34 Million | +25.57% |
| 2020-12-31 | $24.16 Million | +169.47% |
| 2019-12-31 | $8.97 Million | +127.13% |
| 2018-12-31 | $3.95 Million | -39.83% |
| 2017-12-31 | $6.56 Million | -5.31% |
| 2016-12-31 | $6.93 Million | -41.84% |
| 2015-12-31 | $11.91 Million | +1.55% |
| 2014-12-31 | $11.73 Million | +1975.81% |
| 2013-12-31 | $565.17K | -23.91% |
| 2012-12-31 | $742.75K | +5.49% |
| 2011-12-31 | $704.09K | -73.96% |
| 2010-12-31 | $2.70 Million | -77.46% |
| 2009-12-31 | $11.99 Million | -47.86% |
| 2008-12-31 | $23.00 Million | -11.93% |
| 2007-12-31 | $26.12 Million | +198.88% |
| 2006-12-31 | $8.74 Million | +24.03% |
| 2005-12-31 | $7.05 Million | +91.34% |
| 2004-12-31 | $3.68 Million | -30.23% |
| 2003-12-31 | $5.28 Million | -69.49% |
| 2002-12-31 | $17.30 Million | -24.81% |
| 2001-12-31 | $23.01 Million | +86.24% |
| 2000-12-31 | $12.35 Million | +26.05% |
| 1999-12-31 | $9.80 Million | +53.13% |
| 1998-12-31 | $6.40 Million | +12.28% |
| 1997-12-31 | $5.70 Million | -10.94% |
| 1996-12-31 | $6.40 Million | -1.54% |
| 1995-12-31 | $6.50 Million | +983.33% |
| 1994-12-31 | $600.00K | -- |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more